1. Safety and efficacy of low-dose esterified estrogens and methyltestosterone, alone or combined, for the treatment of hot flashes in menopausal women: a randomized, double-blind, placebo-controlled study 
James Liu, M.D., Adam Allgood, Pharm.D., Leonard R. Derogatis, Ph.D., Stephen Swanson, M.D., Michael O’Mahony, M.D., Bertrand Nedoss, M.D., Herbert Soper, M.D., Edward Zbella, M.D., Svetlana Vladimirovna Prokofieva, M.D., Lisa Zipfel, M.S., Chun-Yuan Guo, M.D., Ph.D. 
Fertility and Sterility 
Volume 95, Issue 1, Pages (January 2011)
DOI: /j.fertnstert
Copyright © 2011 American Society for Reproductive Medicine Terms and Conditions

2. Figure 1
Mean change from baseline (± SE) in average daily moderate-to-severe hot flash frequency by week. All treatment groups were compared with placebo group. Significant reduction was achieved by week 4 in esterified estrogens (EE) 0.30 mg + methyltestosterone (MT) 0.60 mg, week 5 in esterified estrogens 0.30 mg + methyltestosterone 0.30 mg, week 6 in esterified estrogens 0.45 mg, week 10 in esterified estrogens 0.30 mg, and no significant change at all time points in methyltestosterone 0.60 mg. LOCF = last observation carried forward.
Fertility and Sterility  , DOI: ( /j.fertnstert )
Copyright © 2011 American Society for Reproductive Medicine Terms and Conditions